Patents by Inventor Paul Hasty

Paul Hasty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230233501
    Abstract: Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 27, 2023
    Inventors: Edward Paul HASTY, Dmitri Nickolaevich IVANOV
  • Patent number: 11612580
    Abstract: Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 28, 2023
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Edward Paul Hasty, Dmitri Nickolaevich Ivanov
  • Publication number: 20220096446
    Abstract: Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).
    Type: Application
    Filed: December 2, 2021
    Publication date: March 31, 2022
    Inventors: Zelton Dave SHARP, Randy STRONG, Paul HASTY, Carolina LIVI, Arlan RICHARDSON
  • Patent number: 11191750
    Abstract: Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: December 7, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zelton Dave Sharp, Randy Strong, Paul Hasty, Carolina Livi, Arlan Richardson
  • Patent number: 10842814
    Abstract: Methods and compositions are provided for inhibiting, preventing, ameliorating and/or reducing damage to DNA in non-cancerous cells in a subject undergoing chemotherapeutic treatment and/or radiation treatment of cancer cells in the subject, comprising administering to the subject one or more compounds of arsenic in a therapeutically effective amount prior to chemotherapeutic treatment and/or radiation treatment.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: November 24, 2020
    Assignees: Board of Regents of the University of Texas System, Baylor College of Medicine
    Inventors: Chul Soo Ha, Zhi-Min Yuan, Hang Su, Edward Paul Hasty, Alison A. Bertuch, Maria Monica Gramatges, Gregory P. Swanson
  • Publication number: 20200330442
    Abstract: Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).
    Type: Application
    Filed: June 29, 2020
    Publication date: October 22, 2020
    Inventors: Zelton Dave SHARP, Randy STRONG, Paul HASTY, Carolina LIVI, Arlan RICHARDSON
  • Publication number: 20200253913
    Abstract: Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.
    Type: Application
    Filed: October 16, 2018
    Publication date: August 13, 2020
    Inventors: Edward Paul HASTY, Dmitri Nickolaevich IVANOV
  • Publication number: 20200239969
    Abstract: Provided here are methods of assessing prognosis for a patient who has been diagnosed with a type of cancer by measuring TREX2 mRNA expression in a biological sample from the patient, comparing the TREX2 mRNA expression in the biological sample to a reference value, and providing a prognosis based on alterations in the TREX2 mRNA expression and the type of cancer. Also provided here are methods of treating a patient with myelodysplastic syndrome by administering a therapeutically effective amount of a pharmaceutical composition that decreases TREX2 mRNA expression in the patient.
    Type: Application
    Filed: October 16, 2018
    Publication date: July 30, 2020
    Inventors: Edward Paul HASTY, Vivienne REBEL, Xiaowen ZHANG
  • Publication number: 20190183929
    Abstract: Methods and compositions are provided for inhibiting, preventing, ameliorating and/or reducing damage to DNA in non-cancerous cells in a subject undergoing chemotherapeutic treatment and/or radiation treatment of cancer cells in the subject, comprising administering to the subject one or more compounds of arsenic in a therapeutically effective amount prior to chemotherapeutic treatment and/or radiation treatment.
    Type: Application
    Filed: August 16, 2017
    Publication date: June 20, 2019
    Inventors: Chul Soo Ha, Zhi-Min Yuan, Hang Su, Edward Paul Hasty, Alison A. Bertuch, Maria Monica Gramatges, Gregory P. Swanson
  • Publication number: 20170105974
    Abstract: Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).
    Type: Application
    Filed: October 28, 2016
    Publication date: April 20, 2017
    Inventors: Zelton Dave SHARP, Randy STRONG, Paul HASTY, Carolina LIVI, Arlan RICHARDSON
  • Publication number: 20160030401
    Abstract: Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Inventors: Zelton Dave SHARP, Randy STRONG, Paul HASTY, Carolina LIVI, Arlan RICHARDSON
  • Publication number: 20160015691
    Abstract: Disclosed are methods and compositions for the prevention or inhibition of the growth of endocrine-related adenomas, neoplasia, or dysplasia in a patient who has been identified as being at risk for developing an endocrine tumor or endocrine cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).
    Type: Application
    Filed: March 14, 2014
    Publication date: January 21, 2016
    Inventors: Zelton Dave SHARP, Carolina LIVI, Paul HASTY, Randy STRONG
  • Patent number: 6057104
    Abstract: When a mutation, designated rad51.sup.M1, was generated in the mouse MmRAD51 gene, mutant embryos died shortly after implantation. rad51.sup.M1 cells exhibited hypersensitivity to ionizing radiation, reduced proliferation, programmed cell death and chromosome loss. The disruption of MmRad51 protein--protein interactions stopped cell proliferation and/or reduced cell viability. Several proteins that interact with MmRad51 have been identified including, for example Brca2 and M96. Additionally, Rad51 self-associates via the N-terminal region. When a single residue was changed from a conserved lysine to an alanine, the alteration proved toxic to cells. Moreover, a rad51 allele that lacked the RecA homology region was also deleterious to cells. In view of the above, it is clear that inhibiting MmRad51 function or the function of any molecule that associates with MmRad51, or any molecule in the Rad51 or Rad52 pathways, hinders cell proliferation and/or viability.
    Type: Grant
    Filed: November 5, 1997
    Date of Patent: May 2, 2000
    Assignee: Lexicon Genetics Incorporated
    Inventor: Paul Hasty
  • Patent number: 6057489
    Abstract: The present invention discloses MmRad51-deficient transgenic mice and mouse cells, as well as MmRad51/p53-deficient transgenic mice and mouse cells. Also described is a method of screening for proteins that rescue the senescence phenotype in MmRad51/p53-deficient cells.
    Type: Grant
    Filed: September 12, 1996
    Date of Patent: May 2, 2000
    Assignee: M.D. Anderson Cancer Center
    Inventors: Paul Hasty, Dae-sik Lim
  • Patent number: 6037125
    Abstract: When a mutation, designated rad51.sup.M1, was generated in the mouse MmRAD51 gene, mutant embryos died shortly after implantation. rad51.sup.M1 cells exhibited hypersensitivity to ionizing radiation, reduced proliferation, programmed cell death and chromosome loss. The disruption of MmRad51 rotein-protein interactions stopped cell proliferation and/or reduced cell viability. Several proteins that interact with MmRad51 have been identified including, for example Brca2 and M96. Additionally, Rad51 self-associates via the N-terminal region. When a single residue was changed from a conserved lysine to an alanine, the alteration proved toxic to cells. Moreover, a rad51 allele that lacked the RecA homology region was also deleterious to cells. In view of the above, it is clear that inhibiting MmRad51 function or the function of any molecule that associates with MmRad51, or any molecule in the Rad51 or Rad52 pathways, hinders cell proliferation and/or viability.
    Type: Grant
    Filed: November 5, 1996
    Date of Patent: March 14, 2000
    Assignee: Lexicon Genetics Incorporated
    Inventor: Paul Hasty
  • Patent number: 5955644
    Abstract: Ku deficient cells and transgenic animals are described that comprise at least one allele of the XRCC5 gene that has been mutated by targeted disruption. Fibroblasts derived from XRCC5 mutant embryos and mice were found to prematurely age. These cells displayed decreased growth, slow entry into S phase, altered colony size distribution that favored small colonies, short life span and morphology characteristic of terminal differentiation. Mutant cells were also hypersensitive to .gamma.-radiation. The tissue culture data was at least partly reproduced in vivo because mutant mice grew slower than control littermates. The XRCC5 mutation, designated xrcc5.sup.M1, was a deletion of nucleotides 701-964 that shifted the reading frame. xrcc5.sup.M1 is expected to be null because the deleted allele produced no detectable transcript and because lymphocyte development and V(D)J recombination was severely disrupted.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: September 21, 1999
    Assignee: M.D. Anderson Cancer Center
    Inventors: Paul Hasty, Dae-sik Lim
  • Patent number: 5614396
    Abstract: A method for producing animal cells, chimeric or transgenic non-human animals which contain a desired gene sequence inserted into a predetermined gene sequence. The method permits the production of animal cells and non-human animals which have subtle and precise modifications of gene sequence and expression relative to natural non-human animals.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: March 25, 1997
    Assignee: Baylor College of Medicine
    Inventors: Allan Bradley, Ann Davis, Paul Hasty